Profusa Launches Lumee Monitoring System Targeting $47.9 Billion CRO Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Market Opportunity: Profusa's launch of the Lumee tissue oxygen monitoring system is strategically aimed at the contract research organization (CRO) market, expected to generate immediate service revenue in a $47.9 billion global market, addressing the demand for real-time biological data.
- Technical Advantage: The Lumee products are commercially ready for rapid integration into existing study designs, minimizing implementation risks and enabling CRO partners to offer differentiated services, thereby enhancing client satisfaction.
- Industry Growth: The global pharmaceutical CRO market is projected to expand from approximately $47.9 billion in 2025 to over $91.2 billion by 2034, with a CAGR exceeding 7%, highlighting strong demand for advanced biosensing platforms.
- Leadership Change: Profusa has appointed Sean Givens as Head of Government and Healthcare Research Business, leveraging his 20 years of industry experience to drive commercialization efforts aimed at accelerating drug development decisions and creating a near-term revenue stream.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
